Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Solasia Pharma K.K.
  6. News
  7. Summary
    4597   JP3436500007

SOLASIA PHARMA K.K.

(4597)
  Report
Delayed Japan Exchange  -  01:00:00 2023-02-09 am EST
49.00 JPY    0.00%
2022Solasia Pharma Flags Bigger FY22 Loss Following Unfavorable Results of Cancer Drug Study
MT
2022Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022
CI
2022An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. from ITOCHU Corporation.
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. from ITOCHU Corporation.

11/22/2022 EST

An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. (TSE:4597) from ITOCHU Corporation (TSE:8001) on November 22, 2022.

An unknown buyer completed the acquisition of unknown minority stake in Solasia Pharma K.K. (TSE:4597) from ITOCHU Corporation (TSE:8001) on November 22, 2022.


ę S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
ITOCHU CORPORATION 0.86% 4106 Delayed Quote.-1.81%
SOLASIA PHARMA K.K. 0.00% 49 Delayed Quote.0.00%
All news about SOLASIA PHARMA K.K.
2022Solasia Pharma Flags Bigger FY22 Loss Following Unfavorable Results of Cancer Drug Stud..
MT
2022Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending ..
CI
2022An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. from ITOCHU Cor..
CI
2022Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending ..
CI
2022Solasia Announces Summary of SP-04 PledOx Development Status
CI
2022Solasia Launches Anticancer Injection Darvias
MT
2022Solasia Announces Launch of Darvias« in Japan
BU
2022Solasia Pharma K K : Business Overview of Pipeline Products (first six months of the Fisca..
PU
2022Solasia Pharma K K : Consolidated Financial Results for the First Six Months of the Fiscal..
PU
2022Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending..
CI
More news
Financials
Sales 2022 780 M 5,94 M 5,94 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -3,13x
Yield 2022 -
Capitalization 8 230 M 62,6 M 62,6 M
Capi. / Sales 2022 10,6x
Capi. / Sales 2023 -
Nbr of Employees 27
Free-Float 83,0%
Chart SOLASIA PHARMA K.K.
Duration : Period :
Solasia Pharma K.K. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SOLASIA PHARMA K.K.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 49,00 JPY
Average target price 60,00 JPY
Spread / Average Target 22,4%
EPS Revisions
Managers and Directors
Yoshihiro Arai President & Representative Director
Toshio Miyashita CFO, Director & General Manager-Administration
Yiu Kwan Lau Independent Outside Director
Norikazu Eiki Independent Outside Director
Jiro Mizukawa Independent Outside Director
Sector and Competitors